Competitors
| Companies | Market Cap | G | R | O | W | T | H |
|---|---|---|---|---|---|---|---|
|
AbbVie NYSE:ABBV |
360,32 B | 2,49% | 4/6 | 25,40% | -26,90% | 24,44% | DOWN |
|
Amgen NasdaqGS:AMGN |
188,98 B | 7,37% | 3/6 | 2,72% | -7,66% | 0,81% | UP |
|
Gilead Sciences NasdaqGS:GILD |
168,65 B | 3,30% | 5/6 | 4,53% | -53,98% | 18,13% | UP |
|
Alnylam Pharmaceuticals NasdaqGS:ALNY |
41,24 B | 46,06% | 4/6 | 49,91% | 8,82% | 44,72% | DOWN |
|
Alexion Pharmaceuticals NasdaqGM:ALXN |
40,34 B | 0,00% | 4/4 | 0,00% | 0,00% | -100,00% | UP |
|
Biogen NasdaqGS:BIIB |
26,91 B | -10,57% | 1/6 | -1,25% | 4,90% | 12,63% | UP |
|
Incyte NasdaqGS:INCY |
19,29 B | 41,79% | 5/6 | 8,74% | 26,54% | 9,88% | UP |
|
BioMarin Pharmaceutical NasdaqGS:BMRN |
10,56 B | 12,22% | 5/6 | 45,50% | 60,59% | 71,28% | DOWN |
|
Arrowhead Pharmaceuticals NasdaqGS:ARWR |
9,70 B | 48,13% | 5/6 | -45,97% | 6,20% | 15,52% | UP |
|
Blueprint Medicines NasdaqGS:BPMC |
8,38 B | 45,26% | 4/6 | 42,18% | -48,48% | 0,64% | UP |
|
Cidara Therapeutics NasdaqCM:CDTX |
6,97 B | -59,17% | 2/6 | 0,00% | -652349,57% | -100,00% | UP |
|
Arena Pharmaceuticals NasdaqGM:ARNA |
6,17 B | 0,00% | 0,00% | 0,00% | 0,00% | UP | |
|
Amicus Therapeutics NasdaqGM:FOLD |
4,54 B | 19,97% | 5/6 | 59,76% | -44,89% | 0,28% | UP |
|
Viking Therapeutics NasdaqCM:VKTX |
4,12 B | 0,00% | 0/4 | 0,00% | 0,00% | 180,05% | UP |
|
ACADIA Pharmaceuticals NasdaqGS:ACAD |
3,77 B | 29,02% | 5/6 | 15,27% | -25,84% | 47,13% | DOWN |
|
Travere Therapeutics NasdaqGM:TVTX |
3,72 B | 10,07% | 5/6 | 42,67% | -99,33% | 21,62% | UP |
|
ChemoCentryx NasdaqGS:CCXI |
3,74 B | 0,00% | 0/4 | 0,00% | 0,00% | -100,00% | UP |
|
CymaBay Therapeutics NasdaqGS:CBAY |
3,72 B | 0,00% | 1/4 | 0,00% | 0,00% | -100,00% | UP |
|
Catalyst Pharmaceuticals NasdaqCM:CPRX |
3,18 B | 40,93% | 5/6 | 5,58% | 20,02% | 34,25% | UP |
|
Celldex Therapeutics NasdaqCM:CLDX |
2,70 B | -34,06% | 1/6 | 114,74% | -438,54% | 59,98% | UP |
